Drug intelligence / Profile preview

phenylethynesulfonamide

Development stage
Preclinical
Lead developer
The Wistar Institute
Modality
Small Molecules
Administration
Oral, Intraperitoneal
01

Overview

Phenylethynesulfonamide (PES), also known as pifithrin-mu (PFT-mu), is a small molecule inhibitor of the heat shock protein 70 (HSP70) family, including the constitutively expressed HSC70. It interacts specifically with the C-terminal substrate-binding domain (SBD) of HSP70, disrupting its chaperone activity and interaction with co-chaperones. This interference leads to the aggregation of misfolded proteins, inhibition of autophagy, and destabilization of the HSP90-mediated protein folding machinery, which in turn reduces the levels of oncogenic client proteins such as HER2, AKT, and CDK4. PES has also been shown to inhibit the Anaphase Promoting Complex/Cyclosome (APC/C), inducing G2/M cell cycle arrest. It exhibits selective cytotoxicity toward cancer cells, particularly in models of melanoma and B-cell lymphoma, while sparing normal cells.

Other names
2-phenylethynesulfonamide
02

Targets

DnaK (Mycobacterial DnaK)

Beyond the preview

Go deeper on phenylethynesulfonamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phenylethynesulfonamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call